CerveraRPietteJ-CFontJ, et al.Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum2002; 46: 1019–1027.
2.
MazidiMKatsikiNMikhailidisDP, et al.Associations of serum uric acid with total and cause-specific mortality: findings from individuals and pooling prospective studies. Atherosclerosis2020; 296: 49–58.
3.
RodriguesCEMBonfáECaleiroMTC, et al.Association of arterial events with the coexistence of metabolic syndrome and primary antiphospholipid syndrome. Arthritis Care Res2012; 64(10): 1576–1583.
4.
MiyakisSLockshinMDAtsumiT, et al.International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost2006; 4(2): 295–306.
5.
WisløffFJacobsenEMLiestølS. Laboratory diagnosis of the antiphospholipid syndrome. Thromb Res2002; 108: 263–271.
6.
DesideriGCastaldoGLombardiA, et al.Is it time to revise the normal range of serum uric acid levels?Eur Rev Med Pharmacol Sci2014; 18(9): 1295–1306.
7.
LouthrenooWKasitanonNWichainunR, et al.Effect of minidose aspirin on renal function and renal uric acid handling in healthy young adults. J Clin Rheumatol2002; 8: 299–304.
8.
WadaAHigashiyamaMKuriharaC, et al.Protective effect of luminal uric acid against indomethacin-induced enteropathy: role of antioxidant effect and gut microbiota. Dig Dis Sci2021; Online ahead of print. DOI: 10.1007/s10620-021-06848-z.
